BACKGROUND: Most research on adjustment of women undergoing genetic testing for breast cancer susceptibility has not followed women for more than 6 months after result receipt and has not evaluated curvilinear patterns in general and cancer-specific adjustment. PURPOSE: This study's primary goal was to examine the trajectory of psychological status in women at risk for breast and ovarian cancer prior to undergoing genetic testing through 1 year after BRCA1/2 result receipt. METHODS: Women in the UCLA Familial Cancer Registry completed questionnaires assessing psychological status (i.e., depressive symptoms, negative and positive mood, anxiety, and cancer-related distress) prior to testing and at 1, 6, and 12 months after result receipt. RESULTS: Of 155 women tested, 117 were BRCA1/2- (96 uninformative negative and 21 true negative) and 38 were BRCA1/2+. Linear mixed model analyses revealed a consistent pattern in adjustment indicators, such that the groups did not differ at baseline, but mutation carriers endorsed significantly more depressive symptoms, negative mood, and cancer-specific distress relative to non-mutation carriers at 1 and 6 months after test result receipt (and less positive mood at 6 months only). At 12 months, negative and positive mood returned to baseline levels for mutation carriers, and depressive symptoms approached baseline. At 12 months, the groups differed significantly only on cancer-specific distress, owing to declining distress in non-carriers. Neither having a previous cancer diagnosis nor receiving a true negative versus uninformative negative result predicted reactions to genetic testing. CONCLUSIONS: Genetic testing prompted an increase in general and cancer-specific distress for BRCA1/2+ women, which remitted by 1 year after result receipt.
BACKGROUND: Most research on adjustment of women undergoing genetic testing for breast cancer susceptibility has not followed women for more than 6 months after result receipt and has not evaluated curvilinear patterns in general and cancer-specific adjustment. PURPOSE: This study's primary goal was to examine the trajectory of psychological status in women at risk for breast and ovarian cancer prior to undergoing genetic testing through 1 year after BRCA1/2 result receipt. METHODS:Women in the UCLA Familial Cancer Registry completed questionnaires assessing psychological status (i.e., depressive symptoms, negative and positive mood, anxiety, and cancer-related distress) prior to testing and at 1, 6, and 12 months after result receipt. RESULTS: Of 155 women tested, 117 were BRCA1/2- (96 uninformative negative and 21 true negative) and 38 were BRCA1/2+. Linear mixed model analyses revealed a consistent pattern in adjustment indicators, such that the groups did not differ at baseline, but mutation carriers endorsed significantly more depressive symptoms, negative mood, and cancer-specific distress relative to non-mutation carriers at 1 and 6 months after test result receipt (and less positive mood at 6 months only). At 12 months, negative and positive mood returned to baseline levels for mutation carriers, and depressive symptoms approached baseline. At 12 months, the groups differed significantly only on cancer-specific distress, owing to declining distress in non-carriers. Neither having a previous cancer diagnosis nor receiving a true negative versus uninformative negative result predicted reactions to genetic testing. CONCLUSIONS: Genetic testing prompted an increase in general and cancer-specific distress for BRCA1/2+ women, which remitted by 1 year after result receipt.
Authors: Wolf H Rogowski; Scott D Grosse; Jürgen John; Helena Kääriäinen; Alastair Kent; Ulf Kristofferson; Jörg Schmidtke Journal: J Community Genet Date: 2010-10-16
Authors: Ashley H Woodson; Kimberly I Muse; Heather Lin; Michelle Jackson; Danielle N Mattair; Leslie Schover; Terri Woodard; Laurie McKenzie; Richard L Theriault; Gabriel N Hortobágyi; Banu Arun; Susan K Peterson; Jessica Profato; Jennifer K Litton Journal: Oncologist Date: 2014-06-20
Authors: Lucia Lombardi; Sonia M Bramanti; Alessandra Babore; Liborio Stuppia; Carmen Trumello; Ivana Antonucci; Alessandra Cavallo Journal: Support Care Cancer Date: 2019-06-15 Impact factor: 3.603
Authors: J Wynn; R Ottman; J Duong; A L Wilson; P Ahimaz; J Martinez; R Rabin; E Rosen; R Webster; C Au; M T Cho; C Egan; E Guzman; M Primiano; J E Shaw; R Sisson; R L Klitzman; P S Appelbaum; U Lichter-Konecki; K Anyane-Yeboa; A Iglesias; W K Chung Journal: Clin Genet Date: 2018-03-13 Impact factor: 4.438